Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Tadashi Iida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5491-6012; OpenAlex author ID A5048443511. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 8 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 18

  1. Pretreatment Contrast-Enhanced Harmonic EUS Predicts Pathological Response and Recurrence-Free Survival After Multimodal Treatment in Resectable Pancreatic Can… Co-author DOI 10.1002/jhbp.70180↗
  2. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… Co-author DOI 10.1093/jrr/rrag082↗
  3. Operator-rated puncture performance and first-pass lesion tissue area in pancreatic ductal adenocarcinoma: an exploratory single-center sub-analysis of endosco… Co-author DOI 10.21203/rs.3.rs-11273454/v1↗
  4. Utility of endoscopic ultrasonography elastography as a predictive tool for post-treatment recurrence of resectable pancreatic cancer treated with neoadjuvant … Co-author DOI 10.5946/ce.2025.414↗
  5. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. Co-author DOI 10.1016/j.pan.2025.02.013↗
  6. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  7. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less Co-author DOI 10.21203/rs.3.rs-3014153/v1↗
  8. Comparison of contrast-enhanced transabdominal ultrasonography following endoscopic ultrasonography with GD-EOB-DTPA-enhanced MRI for the sequential diagnosis … Co-author DOI 10.1002/jhbp.1097↗
  9. Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreat… Co-author DOI 10.1007/s00464-021-08981-2↗
  10. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  11. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  12. Author Correction: Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-022-21219-y↗
  13. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1111/pin.13198↗
  14. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … First author DOI 10.1186/s12885-022-09272-2↗
  15. Good and Bad Stroma in Pancreatic Cancer: Relevance of Functional States of Cancer-Associated Fibroblasts. Co-author DOI 10.3390/cancers14143315↗
  16. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.12.022↗
  17. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-021-86979-5↗
  18. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. Co-author DOI 10.1111/jgh.15163↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuya Ishikawa · 16 shared papers, 2020–2026 · strength 2.87
  2. Yasuyuki Mizutani · 14 shared papers, 2022–2026 · strength 2.71
  3. Hiroki Kawashima · 15 shared papers, 2020–2026 · strength 2.65
  4. Kentaro Yamao · 7 shared papers, 2023–2026 · strength 1.72
  5. Eizaburo Ohno · 11 shared papers, 2020–2024 · strength 1.51
  6. Yoshihisa Takada · 5 shared papers, 2025–2026 · strength 1.36
  7. Mitsuhiro Fujishiro · 8 shared papers, 2020–2022 · strength 0.99
  8. Kunio Kataoka · 5 shared papers, 2020–2024 · strength 0.74
  9. Atsushi Enomoto · 5 shared papers, 2022 · strength 0.70
  10. Yoshiki Hirooka · 5 shared papers, 2021–2023 · strength 0.66
  11. Yuichi Kano · 2 shared papers, 2026 · strength 0.59
  12. Masakatsu Yoshikawa · 4 shared papers, 2020–2022 · strength 0.47
  13. Shinji Mii · 3 shared papers, 2022 · strength 0.37
  14. Ryota Ando · 2 shared papers, 2022 · strength 0.32
  15. Kazunori Takeuchi · 1 shared paper, 2026 · strength 0.25
  16. Takeshi Yanagi · 1 shared paper, 2026 · strength 0.25
  17. Reiko Ashida · 1 shared paper, 2026 · strength 0.25
  18. Kenji Yamao · 1 shared paper, 2026 · strength 0.25
  19. Hisashi Haga · 2 shared papers, 2022 · strength 0.24
  20. Atsushi Masamune · 2 shared papers, 2022 · strength 0.24
  21. Kosuke Minaga · 1 shared paper, 2025 · strength 0.22
  22. Mamoru Takenaka · 1 shared paper, 2025 · strength 0.22
  23. Ken Kamata · 1 shared paper, 2025 · strength 0.22
  24. Masatoshi Kudo · 1 shared paper, 2025 · strength 0.22
  25. Kenta Yamada · 2 shared papers, 2020–2021 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.